RT Journal Article
SR Electronic
T1 A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.01.20143966
DO 10.1101/2020.07.01.20143966
A1 Niclas Roxhed
A1 Annika Bendes
A1 Matilda Dale
A1 Cecilia Mattsson
A1 Leo Hanke
A1 Tea Dodig-Crnkovic
A1 Murray Christian
A1 Birthe Meineke
A1 Simon Elsässer
A1 Juni Andréll
A1 Sebastian Havervall
A1 Charlotte Thålin
A1 Carina Eklund
A1 Joakim Dillner
A1 Olof Beck
A1 Cecilia E Thomas
A1 Gerald McInerney
A1 Mun-Gwan Hong
A1 Ben Murrell
A1 Claudia Fredolini
A1 Jochen M Schwenk
YR 2020
UL http://medrxiv.org/content/early/2020/07/02/2020.07.01.20143966.abstract
AB The COVID-19 pandemic has posed a tremendous challenge for the global community. We established a translational approach combining home blood sampling by finger-pricking with multiplexed serology to assess the exposure to the SARS-CoV-2 virus in a general population. The developed procedure determines the immune response in multiplexed assays against several spike (S, here denoted SPK), receptor binding domain (RBD) and nucleocapsid (NCP) proteins in eluates from dried capillary blood. The seroprevalence was then determined in two study sets by mailing 1000 blood sampling kits to random households in urban Stockholm during early and late April 2020, respectively. After receiving 55% (1097/2000) of the cards back within three weeks, 80% (878/1097) were suitable for the analyses of IgG and IgM titers. The data revealed diverse pattern of immune response, thus seroprevalence was dependent on the antigen, immunoglobulin class, stringency to include different antigens, as well as the required analytical performance. Applying unsupervised dimensionality reduction to the combined IgG and IgM data, 4.4% (19/435; 95% CI: 2.4%-6.3%) and 6.3% (28/443; 95% CI: 4.1%-8.6%) of the samples clustered with convalescent controls. Using overlapping scores from at least two SPK antigens, prevalence rates reached 10.1% (44/435; 95% CI: 7.3%-12.9%) in study set 1 and 10.8% (48/443; 95% CI: 7.9%-13.7%). Measuring the immune response against several SARS-CoV-2 proteins in a multiplexed workflow can provide valuable insights about the serological diversity and improve the certainty of the classification. Combining such assays with home-sampling of blood presents a viable strategy for individual-level diagnostics and towards an unbiased assessment of the seroprevalence in a population and may serve to improve our understanding about the diversity of COVID-19 etiology.One Sentence Summary A multiplexed serology assay was developed to determine antibodies against SARS-CoV-2 proteins in home-sampled dried blood spots collected by finger pricking.Competing Interest StatementOB and NR are co-founders of Capitainer AB, a company that commercialized the blood collection device for microsampling. All other authors declare no conflicts of interestsFunding StatementThis project is supported by a dedicated COVID-19 grant for Translational Serology to JS from the Knut and Alice Wallenberg Foundation, funds from the Erling-Persson foundation for KTH Center for Precision Medicine (KCAP), KTH and Science for Life Laboratory. LH, BeMu and GM are supported by an EU grant (CoroNAb).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the regional ethical board (EPN Stockholm, Dnr 2015/867-31/1) and the Swedish Ethical Review Authority (EPM, Dnr 2020- 01500). Use of biobanked controls samples was approved by the Swedish Ethical Review Authority (Dnr 2020-02483). At Karolinska University Hospital in Huddinge, corona serology testing as part of a convalescent plasma donation study was approved by the Swedish Ethical Review Authority (Dnr 2020-01479).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNormalized and anonymized serology data of the population studies will be deposited and can be made available for validation purposes and upon reasonable request to the corresponding authors.